<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01071200</url>
  </required_header>
  <id_info>
    <org_study_id>IMP25289</org_study_id>
    <secondary_id>2004-002218-13</secondary_id>
    <nct_id>NCT01071200</nct_id>
    <nct_alias>NCT00267761</nct_alias>
  </id_info>
  <brief_title>Study to Evaluate if the Addition of r-hLH (Luveris®) to FSH From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing ART, Who Required High FSH Dose in a Previous Cycle</brief_title>
  <acronym>Luveris in ART</acronym>
  <official_title>A Phase III, Multicentric, Randomized, Open, Comparative Study to Evaluate if the Addition of Recombinant Human Luteinising Hormone [r-hLH (Luveris®)] to Follicle Stimulating Hormone (FSH) From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing Assisted Reproduction Technology (ART), Who Required High FSH Dose in a Previous Cycle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Serono S.P.A., Italy</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck KGaA, Darmstadt, Germany</source>
  <brief_summary>
    <textblock>
      The present study was designed to investigate, in hyporesponder subjects, that required in a&#xD;
      previous assisted reproductive technologies (ART) cycle follicle stimulating hormone (FSH)&#xD;
      &gt;3500 International Unit (IU), the possibility to decrease through recombinant human&#xD;
      luteinizing hormone (r-hLH) supplementation, the FSH amount per oocytes retrieved and in the&#xD;
      mean time to improve the overall cycle outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recombinant human follicle stimulating hormone (r-hFSH), which totally lacks LH activity, is&#xD;
      widely used to induce multiple follicle development in women under pituitary desensitization,&#xD;
      in order to submit them to treatment with assisted reproduction techniques (ART). Clinical&#xD;
      experience from hypogonadotropic-hypogonadic women suggests that while FSH alone is&#xD;
      sufficient to induce follicle development, LH plays a significant part in final follicle&#xD;
      maturation, estrogen synthesis and optimal endometrium growth.&#xD;
&#xD;
      This was a phase III, multicentre, randomized, open-label comparative study to evaluate if&#xD;
      the addition of r-hLH (Luveris) in a 2:1 ratio to FSH from day 8 of ovarian stimulation is&#xD;
      able to decrease the total FSH dose and to improve cycle outcome in 250 infertile women&#xD;
      undergoing ART, who required high FSH dose in a previous cycle (≥ 3500 IU). Subjects who have&#xD;
      met all the inclusion criteria, achieved pituitary desensitization and started controlled&#xD;
      ovarian hyperstimulation (COH) treatment with FSH, on stimulation day 8 (S8) received an&#xD;
      identification number and will be allocated to one of the two following arms:&#xD;
&#xD;
      Arm : FSH + r-hLH (2:1 ratio of FSH:r-hLH), Arm : FSH alone. Treatment with Luveris was&#xD;
      commenced on day 8 (S8) and continued until injection of hCG or cancellation of the treatment&#xD;
      cycle.&#xD;
&#xD;
      Monitoring of stimulation, FSH dose escalation, criteria for injection of hCG, ovum pick up,&#xD;
      embryo transfer and pregnancy confirmation took place according to standard management&#xD;
      practice. The in-vitro fertilization (IVF) or intracytosolic sperm injection (ICSI)&#xD;
      procedure, including luteal phase support, was performed according to each centres' normal&#xD;
      procedures.&#xD;
&#xD;
      The subjects were followed up and the treatment outcome (menstruation or pregnancy) was&#xD;
      recorded. The delivery outcome for any pregnant subjects was recorded in the Case Report Form&#xD;
      (CRF).&#xD;
&#xD;
      Information on the delivery outcome for each pregnancy was collected. Information on adverse&#xD;
      events was collected during the study period.&#xD;
&#xD;
      OBJECTIVES&#xD;
&#xD;
      The primary objective of the study was:&#xD;
&#xD;
      To determine whether the addition of r-hLH (Luveris) from day 8 of ovarian stimulation&#xD;
      reduces the FSH dose needed to obtain/retrieve each oocyte.&#xD;
&#xD;
      The secondary objectives of the study were:&#xD;
&#xD;
        -  To determine whether the addition of Luveris to FSH at day 8 of ovarian stimulation&#xD;
           improves cycle outcome based on secondary endpoints&#xD;
&#xD;
        -  To determine the safety of Luveris in this indication&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Dose of Follicular Stimulating Hormone (FSH) for Retrieved Oocytes</measure>
    <time_frame>Baseline (Stimulation day 8 [S8]) until hCG day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Total Follicle Stimulating Hormone (FSH) and Recombinant Human Luteinizing Hormone (r-hLH) Dose</measure>
    <time_frame>Baseline (S8) until hCG day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Ovarian Stimulation Days</measure>
    <time_frame>Baseline (S8) until hCG day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Oestradiol (E2) Levels at Human Choriogonadotropin (hCG) Day</measure>
    <time_frame>Baseline (S8) and hCG day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Total Number of Retrieved Oocytes</measure>
    <time_frame>34-36 hours post-hCG (OPU)</time_frame>
    <description>Mean number of oocytes retrieved on the day of ovum pick up (OPU) was counted. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Mature Oocytes (Metaphase II)</measure>
    <time_frame>34-36 hours post-hCG (OPU)</time_frame>
    <description>Mean number of metaphase II oocytes was counted for participants undergoing ovum pick up for IntraCytoplasmic Sperm Injection (ICSI). ICSI is a procedure in which a single spermatozoon is injected into the oocyte cytoplasm. Metaphase II stage of the oocyte was classified as the time at which the first polar body was observed microscopically. Metaphase II oocytes are a sub-group of the total number of oocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization Rate</measure>
    <time_frame>12-18 day post-hCG and/or Week 7</time_frame>
    <description>Fertilization rate was measured as the ratio between number of fertilized oocytes and number of inseminated oocytes (maximum 3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Obtained Embryos</measure>
    <time_frame>Day 3 post-hCG (Embryo transfer [ET])</time_frame>
    <description>Total number of obtained embryos with maximum 3 inseminated oocytes was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Transferred Embryos</measure>
    <time_frame>Day 3 post-hCG (ET)</time_frame>
    <description>Embryo transfer is the procedure in which one or more embryos are placed in the uterus or Fallopian tube.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pregnancy</measure>
    <time_frame>12-18 day post-hCG and/or Week 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Pregnancy</measure>
    <time_frame>12-18 day post-hCG and/or Week 7</time_frame>
    <description>Clinical pregnancy is defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Implantation</measure>
    <time_frame>12-18 day post-hCG and/or Week 7</time_frame>
    <description>Implantation is the attachment and subsequent penetration by the zona-free blastocyst (usually in the endometrium) that starts five to seven days after fertilization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ovarian Hyper Stimulation Syndrome (OHSS)</measure>
    <time_frame>Baseline (S8) until 12-18 day post-hCG and/or Week 7</time_frame>
    <description>OHSS is an exaggerated systemic response to ovarian stimulation characterized by a wide spectrum of clinical and laboratory manifestations. It is classified as mild, moderate or severe according to the degree of abdominal distention, ovarian enlargement and respiratory, haemodynamic and metabolic complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cycles Cancelled Due to Risk of OHSS</measure>
    <time_frame>Baseline (S8) until 12-18 day post-hCG and/or Week 7</time_frame>
    <description>OHSS is an exaggerated systemic response to ovarian stimulation characterized by a wide spectrum of clinical and laboratory manifestations. It is classified as mild, moderate or severe according to the degree of abdominal distention, ovarian enlargement and respiratory, haemodynamic and metabolic complications.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>Reproductive Techniques, Assisted</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects treated with r-hFSH and r-hLH (2:1 ratio of r-hFSH:r-hLH)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects treated with r-hFSH alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH)</intervention_name>
    <description>One r-hFSH and one r-hLH injection subcutaneously (s.c.) once daily during the treatment phase from Day 8 of stimulation until injection of human chorionic gonadotropin (hCG) or cancellation of the treatment cycle.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>r-hLH</other_name>
    <other_name>r-hFSH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>r-hFSH</intervention_name>
    <description>One r-hFSH injection s.c. once daily during the treatment phase from Day 8 of stimulation until injection of hCG or cancellation of the treatment cycle.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pre-menopausal infertile woman, aged 18 to 40 years inclusive, who wishes to conceive&#xD;
&#xD;
          -  Regular, spontaneous menstrual cycle of 25-35 days&#xD;
&#xD;
          -  Body mass index (BMI) ≤ 28&#xD;
&#xD;
          -  FSH ≤ 10 IU/L (follicular phase, days 2-5)&#xD;
&#xD;
          -  Prolactin (PRL) within the normal ranges&#xD;
&#xD;
          -  Evidence of both ovaries by ultrasound scan&#xD;
&#xD;
          -  Women undergoing IVF-Embryo Transfer (ET) or ICSI, down regulated with Gonadotropin&#xD;
             releasing hormone analogues (GnRHa) (daily dose) under controlled ovarian&#xD;
             hyperstimulation (COH) with FSH&#xD;
&#xD;
          -  Washout &gt; 90 days from last dose of clomiphene or gonadotrophin, before ongoing COH&#xD;
             cycle&#xD;
&#xD;
          -  Only one previous IVF-ET or ICSI cycle (in the last 9 months preceding the ongoing COH&#xD;
             cycle) resulted in a hypo-response properly documented (from 6 to 12 oocytes with a&#xD;
             total FSH dose ≥ 4000 IU)&#xD;
&#xD;
          -  Negative pregnancy hCG test (urine or blood sample) before the ongoing COH cycles&#xD;
&#xD;
          -  Willing and able to comply with the protocol for the duration of the study&#xD;
&#xD;
          -  Written informed consent before applying any procedure related to the study protocol,&#xD;
             which is not part of routine medical care, with the understanding that consent may be&#xD;
             withdrawn by the subject at any time, without prejudice on their future medical care&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Oligo/Anovulatory cycles (World Health Organization [WHO] I and II)&#xD;
&#xD;
          -  Male partner azoospermia (assessed within the last 12 months)&#xD;
&#xD;
          -  Follicular phase (day 2-5) FSH &gt; 10 IU/L even if only once observed in the medical&#xD;
             history&#xD;
&#xD;
          -  Abnormal cervical cytology (assessed within the last 12 months)&#xD;
&#xD;
          -  History of unexplained gynecologic hemorrhage&#xD;
&#xD;
          -  Any contraindication to pregnancy&#xD;
&#xD;
          -  Known allergy to gonadotrophin&#xD;
&#xD;
          -  Any clinically important systemic disease (e.g. insulin-dependent diabetes mellitus,&#xD;
             epilepsy, serious migraine, intermittent purpura, hepatic, renal or cardiovascular&#xD;
             disease, serious corticoid-dependent asthma) which constitutes a contraindication to&#xD;
             gonadotropin use&#xD;
&#xD;
          -  Any medical condition which, according to the investigator's judgement, may affect the&#xD;
             absorption, distribution, metabolism or excretion of the drug. In case of doubt,&#xD;
             inclusion of the subject in question should be discussed with the Medical Responsible&#xD;
             of Serono&#xD;
&#xD;
          -  Known Human Immunodeficiency Virus (HIV) positivity&#xD;
&#xD;
          -  Any substance abuse or history of drugs or alcohol abuse within the past 5 years&#xD;
&#xD;
          -  Prior inclusion in the present study or simultaneous inclusion in a clinical study of&#xD;
             another drug&#xD;
&#xD;
          -  Refusal or inability to comply with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salvatore Longobardi</last_name>
    <role>Study Director</role>
    <affiliation>Merck Serono S.P.A., Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Merck Serono S.p.A.</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>February 18, 2010</study_first_submitted>
  <study_first_submitted_qc>February 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2010</study_first_posted>
  <results_first_submitted>May 14, 2012</results_first_submitted>
  <results_first_submitted_qc>June 28, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 14, 2012</results_first_posted>
  <last_update_submitted>December 2, 2013</last_update_submitted>
  <last_update_submitted_qc>December 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Reproductive Techniques, Assisted</keyword>
  <keyword>Recombinant human follicle stimulating hormone (r-hFSH)</keyword>
  <keyword>Recombinant leutinizing hormone (r-hLH)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FSH + rhLH</title>
          <description>Follicle-stimulating hormone (FSH) injection administered according to investigator's discretion till Day 8 of stimulation period (S8) and treatment with recombinant human luteinizing hormone (rhLH, Luveris) injection 150 International Units (IU) subcutaneously (s.c.) daily was started from S8 until recombinant human choriogonadotropin (r-hCG) administration day. r-hLH was administered in a 2:1 ratio (FSH:r-hLH).</description>
        </group>
        <group group_id="P2">
          <title>Follicle-stimulating Hormone (FSH)</title>
          <description>FSH injection s.c. administered according to investigator's discretion till r-hCG administration day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of ovarian response</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No fertilization</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No oocytes retrieved</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ovarian Hyper Stimulation Syndrome</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No viable embryos</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FSH + rhLH</title>
          <description>Follicle-stimulating hormone (FSH) injection administered according to investigator's discretion till Day 8 of stimulation period (S8) and treatment with recombinant human luteinizing hormone (rhLH, Luveris) injection 150 International Units (IU) subcutaneously (s.c.) daily was started from S8 until recombinant human choriogonadotropin (r-hCG) administration day. r-hLH was administered in a 2:1 ratio (FSH:r-hLH).</description>
        </group>
        <group group_id="B2">
          <title>Follicle-stimulating Hormone (FSH)</title>
          <description>FSH injection s.c. administered according to investigator's discretion till r-hCG administration day.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="67"/>
            <count group_id="B2" value="66"/>
            <count group_id="B3" value="133"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.6" spread="2.9"/>
                    <measurement group_id="B2" value="35.0" spread="3.8"/>
                    <measurement group_id="B3" value="35.3" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Dose of Follicular Stimulating Hormone (FSH) for Retrieved Oocytes</title>
        <time_frame>Baseline (Stimulation day 8 [S8]) until hCG day</time_frame>
        <population>Modified intention-to-treat (mITT) population included all randomized participants who entered in the experimental phase at S8. Here &quot;N&quot; represents number of participants analyzed for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>FSH + rhLH</title>
            <description>Follicle-stimulating hormone (FSH) injection administered according to investigator's discretion till Day 8 of stimulation period (S8) and treatment with recombinant human luteinizing hormone (rhLH, Luveris) injection 150 International Units (IU) subcutaneously (s.c.) daily was started from S8 until recombinant human choriogonadotropin (r-hCG) administration day. r-hLH was administered in a 2:1 ratio (FSH:r-hLH).</description>
          </group>
          <group group_id="O2">
            <title>Follicle-stimulating Hormone (FSH)</title>
            <description>FSH injection administered according to investigator's discretion till r-hCG administration day.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Dose of Follicular Stimulating Hormone (FSH) for Retrieved Oocytes</title>
          <population>Modified intention-to-treat (mITT) population included all randomized participants who entered in the experimental phase at S8. Here &quot;N&quot; represents number of participants analyzed for this measure.</population>
          <units>IU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (S8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="904.6" spread="1068.1"/>
                    <measurement group_id="O2" value="703.3" spread="924.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (S8) until hCG day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="388.5" spread="631.3"/>
                    <measurement group_id="O2" value="318.5" spread="534.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Total Follicle Stimulating Hormone (FSH) and Recombinant Human Luteinizing Hormone (r-hLH) Dose</title>
        <time_frame>Baseline (S8) until hCG day</time_frame>
        <population>mITT population included all randomized participants who entered in the experimental phase at S8.</population>
        <group_list>
          <group group_id="O1">
            <title>FSH + rhLH</title>
            <description>Follicle-stimulating hormone (FSH) injection administered according to investigator's discretion till Day 8 of stimulation period (S8) and treatment with recombinant human luteinizing hormone (rhLH, Luveris) injection 150 International Units (IU) subcutaneously (s.c.) daily was started from S8 until recombinant human choriogonadotropin (r-hCG) administration day. r-hLH was administered in a 2:1 ratio (FSH:r-hLH).</description>
          </group>
          <group group_id="O2">
            <title>Follicle-stimulating Hormone (FSH)</title>
            <description>FSH injection administered according to investigator's discretion till r-hCG administration day.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Total Follicle Stimulating Hormone (FSH) and Recombinant Human Luteinizing Hormone (r-hLH) Dose</title>
          <population>mITT population included all randomized participants who entered in the experimental phase at S8.</population>
          <units>IU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total FSH dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1434.0" spread="678.1"/>
                    <measurement group_id="O2" value="1595.0" spread="796.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total r-hLH dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="575.9" spread="273.0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Ovarian Stimulation Days</title>
        <time_frame>Baseline (S8) until hCG day</time_frame>
        <population>mITT population included all randomized participants who entered in the experimental phase at S8.</population>
        <group_list>
          <group group_id="O1">
            <title>FSH + rhLH</title>
            <description>Follicle-stimulating hormone (FSH) injection administered according to investigator's discretion till Day 8 of stimulation period (S8) and treatment with recombinant human luteinizing hormone (rhLH, Luveris) injection 150 International Units (IU) subcutaneously (s.c.) daily was started from S8 until recombinant human choriogonadotropin (r-hCG) administration day. r-hLH was administered in a 2:1 ratio (FSH:r-hLH).</description>
          </group>
          <group group_id="O2">
            <title>Follicle-stimulating Hormone (FSH)</title>
            <description>FSH injection administered according to investigator's discretion till r-hCG administration day.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Ovarian Stimulation Days</title>
          <population>mITT population included all randomized participants who entered in the experimental phase at S8.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="2.0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="4.8" lower_limit="1.0" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Oestradiol (E2) Levels at Human Choriogonadotropin (hCG) Day</title>
        <time_frame>Baseline (S8) and hCG day</time_frame>
        <population>mITT population included all randomized participants who entered in the experimental phase at S8. Here &quot;N&quot; represents number of participants analyzed and &quot;n&quot; represents the number of participants with plasma E2 levels at specified time points for respective treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>FSH + rhLH</title>
            <description>Follicle-stimulating hormone (FSH) injection administered according to investigator's discretion till Day 8 of stimulation period (S8) and treatment with recombinant human luteinizing hormone (rhLH, Luveris) injection 150 International Units (IU) subcutaneously (s.c.) daily was started from S8 until recombinant human choriogonadotropin (r-hCG) administration day. r-hLH was administered in a 2:1 ratio (FSH:r-hLH).</description>
          </group>
          <group group_id="O2">
            <title>Follicle-stimulating Hormone (FSH)</title>
            <description>FSH injection administered according to investigator's discretion till r-hCG administration day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Oestradiol (E2) Levels at Human Choriogonadotropin (hCG) Day</title>
          <population>mITT population included all randomized participants who entered in the experimental phase at S8. Here &quot;N&quot; represents number of participants analyzed and &quot;n&quot; represents the number of participants with plasma E2 levels at specified time points for respective treatment groups.</population>
          <units>picogram/milliter (pg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n = 59,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="516.1" spread="353.6"/>
                    <measurement group_id="O2" value="518.9" spread="334.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at hCG day (n = 40,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1391.6" spread="743.4"/>
                    <measurement group_id="O2" value="1179.9" spread="746.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change at hCG day : Wilcoxon two sample test was used to calculate p-value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>Wilcoxon two sample test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Total Number of Retrieved Oocytes</title>
        <description>Mean number of oocytes retrieved on the day of ovum pick up (OPU) was counted. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.</description>
        <time_frame>34-36 hours post-hCG (OPU)</time_frame>
        <population>mITT population included all randomized participants who entered in the experimental phase at S8.</population>
        <group_list>
          <group group_id="O1">
            <title>FSH + rhLH</title>
            <description>Follicle-stimulating hormone (FSH) injection administered according to investigator's discretion till Day 8 of stimulation period (S8) and treatment with recombinant human luteinizing hormone (rhLH, Luveris) injection 150 International Units (IU) subcutaneously (s.c.) daily was started from S8 until recombinant human choriogonadotropin (r-hCG) administration day. r-hLH was administered in a 2:1 ratio (FSH:r-hLH).</description>
          </group>
          <group group_id="O2">
            <title>Follicle-stimulating Hormone (FSH)</title>
            <description>FSH injection administered according to investigator's discretion till r-hCG administration day.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Total Number of Retrieved Oocytes</title>
          <description>Mean number of oocytes retrieved on the day of ovum pick up (OPU) was counted. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.</description>
          <population>mITT population included all randomized participants who entered in the experimental phase at S8.</population>
          <units>oocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="4.6"/>
                    <measurement group_id="O2" value="7.8" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Mature Oocytes (Metaphase II)</title>
        <description>Mean number of metaphase II oocytes was counted for participants undergoing ovum pick up for IntraCytoplasmic Sperm Injection (ICSI). ICSI is a procedure in which a single spermatozoon is injected into the oocyte cytoplasm. Metaphase II stage of the oocyte was classified as the time at which the first polar body was observed microscopically. Metaphase II oocytes are a sub-group of the total number of oocytes.</description>
        <time_frame>34-36 hours post-hCG (OPU)</time_frame>
        <population>mITT population included all randomized participants who entered in the experimental phase at S8. Here &quot;N&quot; represents those participants undergoing ICSI whose oocytes were assessed for maturity (Metaphase II) using a microscope.</population>
        <group_list>
          <group group_id="O1">
            <title>FSH + rhLH</title>
            <description>Follicle-stimulating hormone (FSH) injection administered according to investigator's discretion till Day 8 of stimulation period (S8) and treatment with recombinant human luteinizing hormone (rhLH, Luveris) injection 150 International Units (IU) subcutaneously (s.c.) daily was started from S8 until recombinant human choriogonadotropin (r-hCG) administration day. r-hLH was administered in a 2:1 ratio (FSH:r-hLH).</description>
          </group>
          <group group_id="O2">
            <title>Follicle-stimulating Hormone (FSH)</title>
            <description>FSH injection administered according to investigator's discretion till r-hCG administration day.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Mature Oocytes (Metaphase II)</title>
          <description>Mean number of metaphase II oocytes was counted for participants undergoing ovum pick up for IntraCytoplasmic Sperm Injection (ICSI). ICSI is a procedure in which a single spermatozoon is injected into the oocyte cytoplasm. Metaphase II stage of the oocyte was classified as the time at which the first polar body was observed microscopically. Metaphase II oocytes are a sub-group of the total number of oocytes.</description>
          <population>mITT population included all randomized participants who entered in the experimental phase at S8. Here &quot;N&quot; represents those participants undergoing ICSI whose oocytes were assessed for maturity (Metaphase II) using a microscope.</population>
          <units>Metaphase II Oocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="3.7"/>
                    <measurement group_id="O2" value="5.7" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fertilization Rate</title>
        <description>Fertilization rate was measured as the ratio between number of fertilized oocytes and number of inseminated oocytes (maximum 3).</description>
        <time_frame>12-18 day post-hCG and/or Week 7</time_frame>
        <population>mITT population included all randomized participants who entered in the experimental phase at S8.</population>
        <group_list>
          <group group_id="O1">
            <title>FSH + rhLH</title>
            <description>Follicle-stimulating hormone (FSH) injection administered according to investigator's discretion till Day 8 of stimulation period (S8) and treatment with recombinant human luteinizing hormone (rhLH, Luveris) injection 150 International Units (IU) subcutaneously (s.c.) daily was started from S8 until recombinant human choriogonadotropin (r-hCG) administration day. r-hLH was administered in a 2:1 ratio (FSH:r-hLH).</description>
          </group>
          <group group_id="O2">
            <title>Follicle-stimulating Hormone (FSH)</title>
            <description>FSH injection administered according to investigator's discretion till r-hCG administration day.</description>
          </group>
        </group_list>
        <measure>
          <title>Fertilization Rate</title>
          <description>Fertilization rate was measured as the ratio between number of fertilized oocytes and number of inseminated oocytes (maximum 3).</description>
          <population>mITT population included all randomized participants who entered in the experimental phase at S8.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="0.29"/>
                    <measurement group_id="O2" value="0.89" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Obtained Embryos</title>
        <description>Total number of obtained embryos with maximum 3 inseminated oocytes was calculated.</description>
        <time_frame>Day 3 post-hCG (Embryo transfer [ET])</time_frame>
        <population>mITT population included all randomized participants who entered in the experimental phase at S8.</population>
        <group_list>
          <group group_id="O1">
            <title>FSH + rhLH</title>
            <description>Follicle-stimulating hormone (FSH) injection administered according to investigator's discretion till Day 8 of stimulation period (S8) and treatment with recombinant human luteinizing hormone (rhLH, Luveris) injection 150 International Units (IU) subcutaneously (s.c.) daily was started from S8 until recombinant human choriogonadotropin (r-hCG) administration day. r-hLH was administered in a 2:1 ratio (FSH:r-hLH).</description>
          </group>
          <group group_id="O2">
            <title>Follicle-stimulating Hormone (FSH)</title>
            <description>FSH injection administered according to investigator's discretion till r-hCG administration day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Obtained Embryos</title>
          <description>Total number of obtained embryos with maximum 3 inseminated oocytes was calculated.</description>
          <population>mITT population included all randomized participants who entered in the experimental phase at S8.</population>
          <units>embryos</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Transferred Embryos</title>
        <description>Embryo transfer is the procedure in which one or more embryos are placed in the uterus or Fallopian tube.</description>
        <time_frame>Day 3 post-hCG (ET)</time_frame>
        <population>mITT population included all randomized participants who entered in the experimental phase at S8.</population>
        <group_list>
          <group group_id="O1">
            <title>FSH + rhLH</title>
            <description>Follicle-stimulating hormone (FSH) injection administered according to investigator's discretion till Day 8 of stimulation period (S8) and treatment with recombinant human luteinizing hormone (rhLH, Luveris) injection 150 International Units (IU) subcutaneously (s.c.) daily was started from S8 until recombinant human choriogonadotropin (r-hCG) administration day. r-hLH was administered in a 2:1 ratio (FSH:r-hLH).</description>
          </group>
          <group group_id="O2">
            <title>Follicle-stimulating Hormone (FSH)</title>
            <description>FSH injection administered according to investigator's discretion till r-hCG administration day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Transferred Embryos</title>
          <description>Embryo transfer is the procedure in which one or more embryos are placed in the uterus or Fallopian tube.</description>
          <population>mITT population included all randomized participants who entered in the experimental phase at S8.</population>
          <units>embryos</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pregnancy</title>
        <time_frame>12-18 day post-hCG and/or Week 7</time_frame>
        <population>mITT population included all randomized participants who entered in the experimental phase at S8.</population>
        <group_list>
          <group group_id="O1">
            <title>FSH + rhLH</title>
            <description>Follicle-stimulating hormone (FSH) injection administered according to investigator's discretion till Day 8 of stimulation period (S8) and treatment with recombinant human luteinizing hormone (rhLH, Luveris) injection 150 International Units (IU) subcutaneously (s.c.) daily was started from S8 until recombinant human choriogonadotropin (r-hCG) administration day. r-hLH was administered in a 2:1 ratio (FSH:r-hLH).</description>
          </group>
          <group group_id="O2">
            <title>Follicle-stimulating Hormone (FSH)</title>
            <description>FSH injection administered according to investigator's discretion till r-hCG administration day.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pregnancy</title>
          <population>mITT population included all randomized participants who entered in the experimental phase at S8.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9"/>
                    <measurement group_id="O2" value="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Pregnancy</title>
        <description>Clinical pregnancy is defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy.</description>
        <time_frame>12-18 day post-hCG and/or Week 7</time_frame>
        <population>mITT population included all randomized participants who entered in the experimental phase at S8.</population>
        <group_list>
          <group group_id="O1">
            <title>FSH + rhLH</title>
            <description>Follicle-stimulating hormone (FSH) injection administered according to investigator's discretion till Day 8 of stimulation period (S8) and treatment with recombinant human luteinizing hormone (rhLH, Luveris) injection 150 International Units (IU) subcutaneously (s.c.) daily was started from S8 until recombinant human choriogonadotropin (r-hCG) administration day. r-hLH was administered in a 2:1 ratio (FSH:r-hLH).</description>
          </group>
          <group group_id="O2">
            <title>Follicle-stimulating Hormone (FSH)</title>
            <description>FSH injection administered according to investigator's discretion till r-hCG administration day.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Pregnancy</title>
          <description>Clinical pregnancy is defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy.</description>
          <population>mITT population included all randomized participants who entered in the experimental phase at S8.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9"/>
                    <measurement group_id="O2" value="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Implantation</title>
        <description>Implantation is the attachment and subsequent penetration by the zona-free blastocyst (usually in the endometrium) that starts five to seven days after fertilization.</description>
        <time_frame>12-18 day post-hCG and/or Week 7</time_frame>
        <population>mITT population included all randomized participants who entered in the experimental phase at S8.</population>
        <group_list>
          <group group_id="O1">
            <title>FSH + rhLH</title>
            <description>Follicle-stimulating hormone (FSH) injection administered according to investigator's discretion till Day 8 of stimulation period (S8) and treatment with recombinant human luteinizing hormone (rhLH, Luveris) injection 150 International Units (IU) subcutaneously (s.c.) daily was started from S8 until recombinant human choriogonadotropin (r-hCG) administration day. r-hLH was administered in a 2:1 ratio (FSH:r-hLH).</description>
          </group>
          <group group_id="O2">
            <title>Follicle-stimulating Hormone (FSH)</title>
            <description>FSH injection administered according to investigator's discretion till r-hCG administration day.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Implantation</title>
          <description>Implantation is the attachment and subsequent penetration by the zona-free blastocyst (usually in the endometrium) that starts five to seven days after fertilization.</description>
          <population>mITT population included all randomized participants who entered in the experimental phase at S8.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.38"/>
                    <measurement group_id="O2" value="11.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ovarian Hyper Stimulation Syndrome (OHSS)</title>
        <description>OHSS is an exaggerated systemic response to ovarian stimulation characterized by a wide spectrum of clinical and laboratory manifestations. It is classified as mild, moderate or severe according to the degree of abdominal distention, ovarian enlargement and respiratory, haemodynamic and metabolic complications.</description>
        <time_frame>Baseline (S8) until 12-18 day post-hCG and/or Week 7</time_frame>
        <population>Safety population included all the randomized participants who received at least one dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>FSH + rhLH</title>
            <description>Follicle-stimulating hormone (FSH) injection administered according to investigator's discretion till Day 8 of stimulation period (S8) and treatment with recombinant human luteinizing hormone (rhLH, Luveris) injection 150 International Units (IU) subcutaneously (s.c.) daily was started from S8 until recombinant human choriogonadotropin (r-hCG) administration day. r-hLH was administered in a 2:1 ratio (FSH:r-hLH).</description>
          </group>
          <group group_id="O2">
            <title>Follicle-stimulating Hormone (FSH)</title>
            <description>FSH injection administered according to investigator's discretion till r-hCG administration day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ovarian Hyper Stimulation Syndrome (OHSS)</title>
          <description>OHSS is an exaggerated systemic response to ovarian stimulation characterized by a wide spectrum of clinical and laboratory manifestations. It is classified as mild, moderate or severe according to the degree of abdominal distention, ovarian enlargement and respiratory, haemodynamic and metabolic complications.</description>
          <population>Safety population included all the randomized participants who received at least one dose of the study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild OHSS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate OHSS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe OHSS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cycles Cancelled Due to Risk of OHSS</title>
        <description>OHSS is an exaggerated systemic response to ovarian stimulation characterized by a wide spectrum of clinical and laboratory manifestations. It is classified as mild, moderate or severe according to the degree of abdominal distention, ovarian enlargement and respiratory, haemodynamic and metabolic complications.</description>
        <time_frame>Baseline (S8) until 12-18 day post-hCG and/or Week 7</time_frame>
        <population>Safety population included all the randomized participants who received at least one dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>FSH + rhLH</title>
            <description>Follicle-stimulating hormone (FSH) injection administered according to investigator's discretion till Day 8 of stimulation period (S8) and treatment with recombinant human luteinizing hormone (rhLH, Luveris) injection 150 International Units (IU) subcutaneously (s.c.) daily was started from S8 until recombinant human choriogonadotropin (r-hCG) administration day. r-hLH was administered in a 2:1 ratio (FSH:r-hLH).</description>
          </group>
          <group group_id="O2">
            <title>Follicle-stimulating Hormone (FSH)</title>
            <description>FSH injection administered according to investigator's discretion till r-hCG administration day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cycles Cancelled Due to Risk of OHSS</title>
          <description>OHSS is an exaggerated systemic response to ovarian stimulation characterized by a wide spectrum of clinical and laboratory manifestations. It is classified as mild, moderate or severe according to the degree of abdominal distention, ovarian enlargement and respiratory, haemodynamic and metabolic complications.</description>
          <population>Safety population included all the randomized participants who received at least one dose of the study drug.</population>
          <units>cycles</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs are collected on an ongoing basis from day of written informed consent. All new AEs must be recorded until the post-treatment safety, on day 12-18 post-hCG administration. AEs are classified as pre-treatment, treatment-emergent and post-treatment.</time_frame>
      <desc>Pre-Treatment:Medical conditions present at the initial study visit that did not worsen in severity or frequency during the study;Treatment-Emergent: If the onset date of the AE was on or after the first dose date of the study medication; Post-Treatment: If the onset date of the AE was post-hCG Days 12 - 18 for participants who completed the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>FSH + rhLH</title>
          <description>Follicle-stimulating hormone (FSH) injection administered according to investigator's discretion till Day 8 of stimulation period (S8) and treatment with recombinant human luteinizing hormone (rhLH, Luveris) injection 150 International Units (IU) subcutaneously (s.c.) daily was started from S8 until recombinant human choriogonadotropin (r-hCG) administration day. r-hLH was administered in a 2:1 ratio (FSH:r-hLH).</description>
        </group>
        <group group_id="E2">
          <title>Follicle-stimulating Hormone (FSH)</title>
          <description>FSH injection administered according to investigator's discretion till r-hCG administration day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Left ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cerclage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian Hyper Stimulation Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Urticaria post intake of food (fish)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Merck KGaA Communication Center</name_or_title>
      <organization>Merck Serono, a division of Merck KGaA</organization>
      <phone>+49-6151-72-5200</phone>
      <email>service@merckgroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

